clinical trial · NCT04814108
A Study of Azenosertib (ZN-c3) in Women With Recurrent or Persistent Uterine Serous Carcinoma
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc·phase2·completed·n = 92
Uterine Serous CarcinomaAzenosertib
brief summary
This is a Phase 2 study to evaluate the clinical activity and safety of ZN-c3 (azenosertib) in adult women with recurrent or persistent uterine serous carcinoma (USC).
started
Jul 28, 2021
primary completion
Oct 22, 2025
completion
Oct 22, 2025
last updated
Mar 18, 2026
detailed description
This is a Phase 2 open-label, multicenter study to evaluate the clinical activity and safety of ZN-c3 (also known as azenosertib; KP-2638) in adult women with recurrent or persistent uterine serous carcinoma (USC).
official title
A Phase 2 Open-Label, Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Adult Women With Recurrent or Persistent Uterine Serous Carcinoma
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol